| Action Summary | This action removes the federal requirement that practitioners obtain a special federal waiver, referred to as “X-Waiver” (or “DEA-X Waiver” or “Buprenorphine Waiver”) to prescribe buprenorphine for the treatment of opioid use disorder, pursuant to Section 1262 of the Consolidated Appropriations Act, 2023. |
| Chapters Affected | Only affects this chapter. |
| Executive Branch Review | This Action is exempt from Article 2 of the Administrative Process Act, but falls within the Executive Branch and will be reviewed by the Governor's Office. |
| RIS Project | Yes [7772] |
|
Is Federal action a driving factor in this regulatory change? If so, please provide a specific reference to the law, regulation
or court case.
Section 1262 of the Consolidated Appropriations Act, 2023.
|
|
| New Periodic Review | This action will not be used to conduct a new periodic review. |
| Name / Title: | Meredith Lee / Policy, Regulations, and Manuals Supervisor |
| Address: |
600 E. Broad St., Suite 1300 Richmond, VA 23219 |
| Email Address: | Meredith.Lee@dmas.virginia.gov |
| Phone: | (804)371-0552 FAX: (804)786-1680 TDD: (800)343-0634 |